癌症治疗新突破,两例血癌病人被彻底治愈

字体 -

由于这个消息非常震撼,还是连夜将它翻成中文,献给诸位,特别是与那些患有癌症疾病的人们分享,以此鼓励那些正在与癌症病魔拼搏的朋友们勇敢面对疾病,勇敢地与病魔抗争。如今初步的成果表明人类离完全征服癌症的那一天已经不远了,希望那些患有癌症的朋友们振作起来,曙光就在前方。

参考译文如下:

刚刚获悉,今天有科学家宣布采用基因治疗法成功的将两位患有血癌的病人治愈,这可以说是人类医学史至今为止第一次将患有血癌的病人治愈。据说是采用病人自身的血细胞抗击功能将癌细胞杀死。

实际上,此次试验一共有三位病人,前两位病人经过一年的治疗身体中的癌细胞全部消失,而第三位病人也明显见效,癌细胞总体数量减少,可以说治疗结果喜人。目前科学家们正在准备用同样的基因疗法去尝试治疗其他类型的癌症。

宾西法尼亚大学基因治疗专家卡尔。俊博士认为次番成效显著,他说“ 我们对此治疗结果感到惊讶,我们只用了一年的时间,我们还需要观察到底这项治疗的耐久性能持续多久?”

他领导的这项研究治疗成果本周三同时被两本颇据权威的医学杂志刊登,这两本杂志分别为”New England Journal of Medicine 和Science Translational Medicine.

这三位患者都是患有病情发展极快的慢性淋巴细胞血癌,简称为CCL。常规治疗这种癌症的办法都是骨髓移植或干细胞移植,通常这两种治疗办法都不是很有效且死亡的风险很高。

科学家们经过数年努力终于找到了提高人体免疫系统自身的能力来战胜癌症的办法。早些时候曾经通过基因改良研制出一种称为血液战士的T细胞,但效果还是有限,这种改良后的细胞并不能产生自身复制且很快消亡。

俊和他的同事们一起经过努力将原来的技术加以改变,采用最新载体将新型基因送到T细胞中去,而产生机械信号告诉T细胞杀死癌细胞并成倍的自身复制自己从 而会杀死更多的癌细胞。结果是具有“系列杀手“细胞直袭癌细胞,将癌细胞杀死。只要癌细胞一产生就会立马被杀死。实际上这也是通常所了解到的T细胞攻击 病毒的方法,俊认为战胜癌症这还是人类有史以来的第一次。

就此次试验来说,从三个病人身体中取血并将T细胞分离出来,然后拿到实验室中去加以改造,分三次将数百万改造后的T细胞再注入到病人的体内。

研究人员描述了一位64岁患者的详细经历,起初治疗持续了两周都没有变化,可而后病人突然出现发冷,呕吐和发烧症状。这位长者和其他两位病人在癌细胞死亡时都出现了同样的症状。实际上这种症状正是基因治疗所产生的。

俊博士讲“当时的症状就像重感冒一样,而感冒症状过后癌症就一下子好了。

主要的并发症是这项技术在杀死癌细胞的同时也会杀死正常的血细胞。到目前为止,病人们已经接受了为期一个月的治疗。

宾西法尼亚的研究人员们还想用这项基因技术试着治疗胰腺癌和卵巢癌。他还说其它一些机构正在尝试用这项技术治疗膀胱癌和脑癌。

位于俄勒冈州的波特兰市癌症研究中心的瓦尔特博士认为次番发现成绩辉煌,可他补充说由于这项研究的规模局限性,要谨慎。他讲 ”这项研究毕竟只是在这三个人的范 围内进行的,三个比一个强,但毕竟不是100个。瓦尔特博士同其他几位科学家就这项研究的评论刊登在新英格兰杂志上。他讲,长久性对这些病人来说是关键,从现在 起一年,或许两年。

可是位于纽约州长岛犹太人医疗中心工作的血癌专家Kanti Rai博士很难控制他的那番热情,人们都知道他对类似的报道大多持有保留态度。

尽管Rai不是这项研究项目的一员但他还是抑制不住内心的激动,说”这项成果太惊人了,绝对令人惊喜“

三个病人都不愿意透露自己的身份,可其中一人以书面形式描述了他的病情,而后由大学方面公开发表 ,据说这个人本身就是位科学家,他认为尽管15年前50岁时被首次诊断出患血癌时并没有那种感觉,但还是可以称自己“非常幸运”

他起初成功的运用化疗治疗多年但后来到了常规药物都无法治疗的地步。而现今,差不多只用了一年的时间,他说“我现在身体非常健康,又恢复了工作,这或许不是永久性的,但我还是宣告胜利了,我赢了,”

NY349-810_2011_151029_high.jpg 原文如下:

NEW YORK, N.Y. - Scientists are reporting the first clear success with a new approach for treating leukemia — turning the patients’ own blood cells into assassins that hunt and destroy their cancer cells.

They’ve only done it in three patients so far, but the results were striking: Two appear cancer-free up to a year after treatment, and the third patient is improved but still has some cancer. Scientists are already preparing to try the same gene therapy technique for other kinds of cancer.

“It worked great. We were surprised it worked as well as it did,” said Dr. Carl June, a gene therapy expert at the University of Pennsylvania. “We’re just a year out now. We need to find out how long these remissions last.”

He led the study, published Wednesday by two journals, New England Journal of Medicine and Science Translational Medicine.

It involved three men with very advanced cases of chronic lymphocytic leukemia, or CLL. The only hope for a cure now is bone marrow or stem cell transplants, which don’t always work and carry a high risk of death.

Scientists have been working for years to find ways to boost the immune system’s ability to fight cancer. Earlier attempts at genetically modifying bloodstream soldiers called T-cells have had limited success; the modified cells didn’t reproduce well and quickly disappeared.

June and his colleagues made changes to the technique, using a novel carrier to deliver the new genes into the T-cells and a signalling mechanism telling the cells to kill and multiply.

That resulted in armies of “serial killer” cells that targeted cancer cells, destroyed them, and went on to kill new cancer as it emerged. It was known that T-cells attack viruses that way, but this is the first time it’s been done against cancer, June said.

For the experiment, blood was taken from each patient and T-cells removed. After they were altered in a lab, millions of the cells were returned to the patient in three infusions.

The researchers described the experience of one 64-year-old patient in detail. There was no change for two weeks, but then he became ill with chills, nausea and fever. He and the other two patients were hit with a condition that occurs when a large number of cancer cells die at the same time — a sign that the gene therapy is working.

“It was like the worse flu of their life,” June said. “But after that, it’s over. They’re well.”

The main complication seems to be that this technique also destroys some other infection-fighting blood cells; so far the patients have been getting monthly treatments for that.

Penn researchers want to test the gene therapy technique in leukemia-related cancers, as well as pancreatic and ovarian cancer, he said. Other institutions are looking at prostate and brain cancer.

Dr. Walter J. Urba of the Providence Cancer Center in Portland, Oregon, called the findings “pretty remarkable” but added a note of caution because of the size of the study.

“It’s still just three patients. Three’s better than one, but it’s not 100,” said Urba, one of the authors of an editorial on the research that appears in the New England Journal.

What happens long-term is key, he said: “What’s it like a year from now, two years from now, for these patients.”

But Dr. Kanti Rai, a blood cancer expert at New York’s Long Island Jewish Medical Center, could hardly contain his enthusiasm, saying he usually is more reserved in his comments on such reports.

“It’s an amazing, amazing kind of achievement,” said Rai, who had no role in the research.

None of the three patients wanted to be identified, but one wrote about his illness, and his statement was provided by the university. The man, himself a scientist, called himself “very lucky,” although he wrote that he didn’t feel that way when he was first diagnosed 15 years ago at age 50.

He was successfully treated over the years with chemotherapy until standard drugs no longer worked.

Now, almost a year since he entered the study, “I’m healthy and still in remission. I know this may not be a permanent condition, but I decided to declare victory and assume that I had won.”

分享博文至:

    2 条评论

  1. 1. Robert Xian - 2011年8月12日 01:09

    由于本人水平有限,错译或理解不当在所难免,还望诸位谅解。

  2. 2. 牧童之家 - 2011年8月12日 14:02

    也听到了这news.. 您做了好事呢。辛苦了。。谢谢好心人

发表评论

您目前尚未登陆,不能发表评论。登陆